For example, when PAPPA, the protease of IGFBP4, was genetically overexpressed in atherosclerosis models (APOE-KO), IGF bioavailability was enhanced due to reduced IGFBP4, resulting in a more severe atherosclerotic plaque formation51. The gene discussed is APOE; the disease is atherosclerosis.